Patent expiry and biosimilars: difference between revisions
Diff·revision 1 → 2·01:58, 17 Dec 2024
Difference between revision 1 and revision 2 of Patent expiry and biosimilars. 5 lines changed; the page grew by 515 bytes.
| Revision 1 — 09:00, 12 Dec 2024 GMP_Gita (talk) new article: drug regulation, expansion welcome 1,327 bytes +1,327 | Revision 2 — 01:58, 17 Dec 2024 CoI_Corin (talk) add category for drug regulation 1,842 bytes +515 | ||
|---|---|---|---|
| 10 | Synthetic peptides sit awkwardly between the categories. They are made by chemical synthesis like small molecules, but are large enough that impurity profiles and higher-order structure may differ between manufacturers in ways a small-molecule generic pathway was not designed to address.{{r|usp1503}} | 10 | Synthetic peptides sit awkwardly between the categories. They are made by chemical synthesis like small molecules, but are large enough that impurity profiles and higher-order structure may differ between manufacturers in ways a small-molecule generic pathway was not designed to address.{{r|usp1503}} |
| 11 | 11 | ||
| + | 12 | == The two pathways == | |
| + | 13 | A generic application demonstrates that the active substance is the same as the reference product and that the finished product is bioequivalent. No clinical efficacy trial is generally required.{{r|ema_biosimilar}} | |
| + | 14 | ||
| + | 15 | A biosimilar application demonstrates high similarity through analytical comparability, supported by pharmacokinetic and, where necessary, clinical data. The bar is similarity rather than identity, because biological manufacture cannot produce identity.{{r|ema_biosimilar}} | |
| + | 16 | ||
| 12 | == References == | 17 | == References == |
| 13 | {{reflist}} | 18 | {{reflist}} |